OpenLB
Open Library of Bioscience
Advanced Search
BioMed research international
2018;2018 8591397.

Involvement of P2X Receptor in Proliferation and Migration of Human Glioma Cells.

Zhenhua Ji, Yuting Xie, Yu Guan, Yujian Zhang, Kin-Sang Cho, Min Ji, Yongping You
Author Information
  1. Zhenhua Ji: Department of Neurosurgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
  2. Yuting Xie: Department of Ophthalmology, Affiliated Hospital of Nantong University, Nantong 226001, China.
  3. Yu Guan: Department of Ophthalmology, Affiliated Hospital of Nantong University, Nantong 226001, China.
  4. Yujian Zhang: Department of Ophthalmology, Affiliated Hospital of Nantong University, Nantong 226001, China.
  5. Kin-Sang Cho: Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
  6. Min Ji: Department of Ophthalmology, Affiliated Hospital of Nantong University, Nantong 226001, China. ORCID
  7. Yongping You: Department of Neurosurgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China. ORCID
PMID: 29546069 DOI: 10.1155/2018/8591397

Abstract

Previous studies have demonstrated that activation of P2X receptors (P2XR) results in the proliferation and migration of some types of tumor. Here, we asked whether and how the activated P2XR contribute to proliferation and migration of human glioma cells. Results showed that the number of P2XR positive cells was increasing with grade of tumor. In U87 and U251 human glioma cell lines, both expressed P2XR and the expression was enhanced by 3'-O-(4-benzoylbenzoyl) ATP (BzATP), the agonist of P2XR, and siRNA. Our results also showed that 10 M BzATP was sufficient to induce the proliferation of glioma cell significantly, while the cell proliferation reached the peak with 100 M BzATP. Also, the migration of U87 and U251 cells was significantly increased upon BzATP treatment. However, the number of apoptotic cells of U87 and U251 was not significantly changed by BzATP. In addition, the expression of ERK, p-ERK, and proliferating cell nuclear antigen (PCNA) protein was increased in BzATP-treated U87 and U251 glioma cells. PD98059, an inhibitor of the MEK/ERK pathway, blocked the increased proliferation and migration of glioma cells activated by BzATP. These results suggest that ERK pathway is involved in the proliferation and migration of glioma cells induced by P2XR activation.

References

  1. Reprod Fertil Dev. 2015 Nov;27(8):1262-71 [PMID: 25782073]
  2. Curr Pharm Des. 2017;23 (1):170-175 [PMID: 27719638]
  3. Tumour Biol. 2016 Oct;37(10 ):13777-13788 [PMID: 27481513]
  4. Cancer Lett. 2008 Feb 18;260(1-2):79-87 [PMID: 18039556]
  5. Sci Rep. 2016 Nov 23;6:37283 [PMID: 27876890]
  6. Oncotarget. 2016 Jun 21;7(25):38892-38907 [PMID: 26646588]
  7. Sci Rep. 2015 Dec 21;5:18417 [PMID: 26687764]
  8. Biomol Ther (Seoul). 2017 Mar 1;25(2):186-193 [PMID: 27829269]
  9. Exp Mol Med. 2011 Jan 31;43(1):7-14 [PMID: 21088470]
  10. Nature. 2014 Oct 9;514(7521):247-51 [PMID: 25119042]
  11. J Immunol. 2012 Aug 1;189(3):1303-10 [PMID: 22753942]
  12. Exp Eye Res. 2016 Dec;153:42-50 [PMID: 27720859]
  13. Purinergic Signal. 2013 Dec;9(4):491-540 [PMID: 23797685]
  14. Int J Biochem Cell Biol. 2013 Jun;45(6):1109-20 [PMID: 23523696]
  15. J Neurosci. 2008 Jun 18;28(25):6393-401 [PMID: 18562610]
  16. Cell Death Dis. 2014 Mar 20;5:e1135 [PMID: 24651438]
  17. Ageing Res Rev. 2015 Nov;24(Pt B):328-42 [PMID: 26478005]
  18. Cancer Res. 2012 Nov 1;72(21):5441-7 [PMID: 23090120]
  19. Biochim Biophys Acta. 2013 Jan;1828(1):79-93 [PMID: 22266266]
  20. Purinergic Signal. 2012 Sep;8(3):629-57 [PMID: 22544529]
  21. J Immunol. 2003 Jun 1;170(11):5728-38 [PMID: 12759456]
  22. Eur J Pharmacol. 2002 Jul 5;447(2-3):261-9 [PMID: 12151017]
  23. Interface Focus. 2013 Jun 6;3(3):20120101 [PMID: 23853707]
  24. J Neurooncol. 2005 Jan;71(2):135-40 [PMID: 15690128]
  25. CNS Neurol Disord Drug Targets. 2012 Sep;11(6):705-21 [PMID: 22963440]
  26. Trends Biochem Sci. 2013 Jan;38(1):20-9 [PMID: 23206935]
  27. Curr Treat Options Neurol. 2008 Jul;10(4):271-84 [PMID: 18579014]
  28. Bone. 2017 Feb;95:91-101 [PMID: 27856358]
  29. J Neuropathol Exp Neurol. 2011 Jan;70(1):13-22 [PMID: 21157381]
  30. Cell Tissue Res. 2002 Dec;310(3):257-70 [PMID: 12457224]
  31. Sci Rep. 2016 Sep 02;6:32602 [PMID: 27586846]
  32. Purinergic Signal. 2012 Dec;8(4):729-39 [PMID: 22644907]
  33. Curr Med Chem. 2015;22(7):819-44 [PMID: 25005189]
  34. Front Cell Neurosci. 2015 Jul 08;9:258 [PMID: 26217184]
  35. Oncol Lett. 2016 Oct;12 (4):2538-2544 [PMID: 27698824]
  36. Hum Mutat. 2017 Jun;38(6):736-744 [PMID: 28326637]
  37. Oncotarget. 2016 Aug 2;7(31):49664-49676 [PMID: 27391069]
  38. Oncol Res. 2017 Sep 21;25(8):1349-1355 [PMID: 28247845]
  39. Biomed Res Int. 2016;2016:9020715 [PMID: 27738636]
  40. Int J Cancer. 2016 Dec 1;139(11):2540-52 [PMID: 27513892]
  41. Biochim Biophys Acta. 2015 Jan;1852(1):120-30 [PMID: 25445541]
  42. Pharm Pat Anal. 2017 Mar;6(2):61-76 [PMID: 28248151]
  43. Purinergic Signal. 2009 Jun;5(2):251-6 [PMID: 19263244]
  44. Mol Neurobiol. 2010 Jun;41(2-3):351-5 [PMID: 20405342]
  45. Neuropharmacology. 2011 Dec;61(8):1210-21 [PMID: 21798274]
  46. Neuropharmacology. 2016 May;104:272-81 [PMID: 26456352]
  47. Sci Rep. 2016 Jun 02;6:27104 [PMID: 27251306]
  48. Mol Biol Cell. 2005 Jul;16(7):3260-72 [PMID: 15901833]
  49. Exp Ther Med. 2015 Oct;10(4):1472-1478 [PMID: 26622509]
  50. Oncogene. 2017 Jan 19;36(3):293-303 [PMID: 27321181]

MeSH Term

Adenosine Triphosphate
Apoptosis
Cell Line, Tumor
Cell Movement
Cell Proliferation
Gene Expression Regulation, Neoplastic
Glioma
Humans
MAP Kinase Signaling System
RNA, Small Interfering
Receptors, Purinergic P2X7

Chemicals

RNA, Small Interfering
Receptors, Purinergic P2X7
3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate
Adenosine Triphosphate
Journal Article

Word Cloud

Created with Highcharts 10.0.0cellsP2XRproliferationgliomaBzATPmigrationU87U251cellresultssignificantlyincreasedactivationP2XtumoractivatedhumanshowednumberexpressionERKpathwayPreviousstudiesdemonstratedreceptorstypesaskedwhethercontributeResultspositiveincreasinggradelinesexpressedenhanced3'-O-4-benzoylbenzoylATPagonistsiRNAalso10 Msufficientinducereachedpeak100 MAlsoupontreatmentHoweverapoptoticchangedadditionp-ERKproliferatingnuclearantigenPCNAproteinBzATP-treatedPD98059inhibitorMEK/ERKblockedsuggestinvolvedinducedInvolvementReceptorProliferationMigrationHumanGliomaCells

Similar Articles

Cited By